Defective DNA repair in hereditary ovarian cancers: Implications for therapy

Area of Science:

• Gynecologic Oncology
• Cancer Genomics
• Molecular Biology

Background:

• Ovarian cancer (OC) is a leading cause of gynecologic cancer mortality.
• Hereditary OCs, including those with BRCA1/2, Fanconi anemia (FA), BRCAness, and Lynch syndrome mutations, represent up to 24% of all OCs.
• Genomic research reveals defective DNA repair pathways as a key driver in hereditary OCs.

Purpose of the Study:

• To review the role of mutated DNA repair pathways in hereditary ovarian cancer.
• To examine the clinical basis for using poly(ADP-ribose) polymerase (PARP) inhibitors and immune checkpoint inhibitors in treating specific OC subtypes.

Main Methods:

• Literature review of genomic data and clinical studies.
• Analysis of DNA repair pathway mutations in hereditary OC.
• Evaluation of targeted therapy efficacy in relation to specific genetic alterations.

Main Results:

• Hereditary OCs often exhibit deficiencies in DNA repair pathways, particularly homologous recombination.
• BRCA1/2, FA-associated, and BRCAness mutations confer sensitivity to PARP inhibitors, though responses can be partial and platinum-dependent.
• Microsatellite instability, linked to DNA mismatch repair deficiency in Lynch syndrome, is associated with efficacy of immune checkpoint inhibitors like pembrolizumab in certain metastatic cancers, including some OCs.

Conclusions:

• Mutations in DNA repair pathways are central to the pathogenesis of hereditary OC syndromes.
• Targeted therapies, including PARP inhibitors and immune checkpoint inhibitors, represent promising novel treatment strategies for distinct hereditary OC subtypes.
• Understanding the molecular basis of hereditary OCs is crucial for optimizing personalized therapeutic approaches.